Gypenoside LI_product_DataBase

Bioactivity	Gypenoside LI, a gypenoside monomer, possesses anti-tumor activity. Gypenoside LI induces cell apoptosis, cell cycle and migration[1][2].
Invitro	Gypenoside LI (0-80 μM) inhibits A549 cells in a dose-dependent manner. Gypenoside LI induces G2/M and arrest apoptosis in A549 cells[1].Gypenoside LI increases intracellular ROS level. Gypenoside LI suppressed migration of A549 cells[1].Gypenoside LI could obviously suppress the expression of CDK1 protein rather thanCDK2 and CDK4 proteins[1].Gypenoside LI inhibits cell proliferation and upregulates expression of miR-128-3p in melanoma cells[2].Gypenoside LI (75 and 29.71 μg/mL) can induce intrinsic apoptosis along with S phase arrest. Gypenoside LI inhibited the colony formation ability of melanoma through inhibition of the Wnt/β-catenin signaling pathway[2].Gypenoside LI induces PARP cleavage, increased the expression of cleaved caspase-9 and BID death agonist, and downregulates the expression of FLIP (long form) and BCl-2 in the A375 and SK-MEL-28 melanoma cells[2]. Cell Viability Assay[1] Cell Line:
Name	Gypenoside LI
CAS	94987-10-7
Formula	C42H72O14
Molar Mass	801.01
Transport	Room temperature in continental US; may vary elsewhere.
Storage	4°C, sealed storage, away from moisture and light *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

PeptideDB